• Novartis AG


  • Alcon Laboratories Inc


Novartis AG (Novartis) proposes to acquire a majority interest in Alcon Laboratories Inc (Alcon). Both Novartis and Alcon have global operations in the research and development, manufacturing and marketing of human health care products. In Australia, Novartis and Alcon's businesses overlap in the vision care sector.

Market definition

Please see the attached Public Competition Assessment.

Competition analysis

Please see the attached Public Competition Assessment.

Public competition assessment

Document title Date
Public Competition Assessment


Document title Date
Final 87B Undertakings


Date Event

ACCC commenced review under the Merger Review Process Guidelines.

Closing date for submissions from interested parties.

In order to allow the ACCC to conduct further inquiries, ACCC timeline suspended. Former proposed date for announcement of ACCC's findings of 27 May 2010 deferred.

Divestiture proposal proffered by Novartis. ACCC commenced market inquiries on divestiture proposal. ACCC timeline recommenced.

ACCC announced it would not oppose the proposed acquisition, subject to court enforceable undertaking offered by Novartis.

87B undertaking accepted by ACCC.